AtriCure, Inc. - Common Stock (ATRC)

60.41
+0.53 (0.89%)
NASDAQ · Last Trade: Nov 3rd, 8:50 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close59.88
Open59.45
Bid56.05
Ask70.00
Day's Range59.10 - 61.54
52 Week Range25.36 - 63.00
Volume1,606,811
Market Cap2.77B
PE Ratio (TTM)-604.10
EPS (TTM)-0.1
Dividend & YieldN/A (N/A)
1 Month Average Volume764,053

Chart

About AtriCure, Inc. - Common Stock (ATRC)

Atricure Inc is a medical device company that focuses on creating innovative solutions for the treatment of atrial fibrillation and other cardiac conditions. The company develops and manufactures specialized devices and technologies designed for minimally invasive surgical procedures, aiming to improve patient outcomes and enhance the efficiency of surgical practices. Atricure's products are utilized by healthcare professionals in various clinical settings, providing effective treatments that address the complexities of heart rhythm disorders. Through continuous research and development, the company strives to advance the field of cardiac care and contribute to the betterment of patient health. Read More

News & Press Releases

What AtriCure (ATRC) Said on Its Q3 Earnings Callmarketbeat.com
AtriCure (NASDAQ:ATRC) reported third-quarter 2026 revenue of $154.5 million, up 15% from a year earlier, as growth in its U.S. open ablation, appendage management and pain management businesses helped lift profitability. Net income was $4.1 million, compared with a net loss of $0.3 million in the
Via MarketBeat · November 3, 2026
AtriCure (NASDAQ:ATRC) Q3 2026 Earnings: EPS Beat, Revenue Inline, Soft Guidance Weighs on Shareschartmill.com
Via Chartmill · November 3, 2026
AtriCure Reports Third Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2026 financial results.
By AtriCure, Inc. · Via Business Wire · November 3, 2026
AtriCure to Participate at Upcoming Investor Conferences
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences.
By AtriCure, Inc. · Via Business Wire · October 26, 2026
AtriCure (NASDAQ:ATRC) Combines Technical Strength With a Breakout Setupchartmill.com
Via Chartmill · October 24, 2026
AtriCure (NASDAQ:ATRC) Profitability Surge Drives After-Hours Rally Despite Inline Revenuechartmill.com
Via Chartmill · July 23, 2026
AtriCure (NASDAQ:ATRC) Q1 Results Beat Estimates as Company Reaches Key Profitability Milestonechartmill.com
Via Chartmill · May 5, 2026
AtriCure to Announce Third Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2026 financial results on Tuesday, November 3, 2026.
By AtriCure, Inc. · Via Business Wire · October 13, 2026
AtriCure CTO Sells 3,657 Sharesfool.com
Privitera executed the sale under a pre-established Rule 10b5-1 trading plan.
Via The Motley Fool · September 12, 2026
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference.
By AtriCure, Inc. · Via Business Wire · August 25, 2026
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growthmarketbeat.com
AtriCure (NASDAQ:ATRC) said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials. Speaking at the Canaccord Genuity G
Via MarketBeat · August 11, 2026
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investorsfool.com
The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.
Via The Motley Fool · August 7, 2026
An AtriCure Director Sold $905,000 in Stock. Here's How to Read Itfool.com
Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.
Via The Motley Fool · August 7, 2026
AtriCure to Participate at Upcoming Investor Conferences
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences.
By AtriCure, Inc. · Via Business Wire · July 27, 2026
AtriCure Q2 Earnings Call Highlightsmarketbeat.com
AtriCure (NASDAQ:ATRC) reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management, appendage management and open ablation franchises while noting continued pressure in minimally invasive
Via MarketBeat · July 23, 2026
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcriptbenzinga.com
AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzinga
Via Benzinga · July 23, 2026
AtriCure Reports Second Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results.
By AtriCure, Inc. · Via Business Wire · July 23, 2026
AtriCure to Announce Second Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026.
By AtriCure, Inc. · Via Business Wire · July 2, 2026
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global Health Care Conference.
By AtriCure, Inc. · Via Business Wire · May 27, 2026
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlookmarketbeat.com
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management. Speaking at a Bank of America fireside
Via MarketBeat · May 12, 2026
AtriCure (ATRC) Q1 2026 Earnings Transcriptfool.com
AtriCure (ATRC) Q1 2026 Earnings Transcript
Via The Motley Fool · May 6, 2026
AtriCure Reports First Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2026 financial results.
By AtriCure, Inc. · Via Business Wire · May 5, 2026
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Bank of America Securities Health Care Conference.
By AtriCure, Inc. · Via Business Wire · April 28, 2026
AtriCure to Announce First Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026.
By AtriCure, Inc. · Via Business Wire · April 14, 2026
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Resetfool.com
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
Via The Motley Fool · March 21, 2026